Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients

IntroductionImmunosuppressive therapy (IST) for acquired hemophilia A (AHA) results in remission within days to months in 60% to 80% of patients. However, little is known regarding the predictors of response. AimThis study aimed to identify the factors that influence response to treatment. MethodsThe data of 42 patients with AHA from three hospitals were retrospectively analyzed. ResultsAll 42 AHA patients received IST; complete treatment data were available for 34 patients. The response rate was 60% among the 5/34 (14.7%) patients who received steroids alone, 70.8% among the 24/34 (70.6%) patients who received steroids plus cyclophosphamide, and 80% among the 5/34 (14.7%) patients who received steroids plus cyclophosphamide and rituximab. Overall, 29/34 (85.3%) patients achieved CR; 4/34 (13.8%) of them relapsed after a median time of 410 (21-1279) days. Adverse events occurred in 14/34 (41.2%) patients: 13/34 (38.2%) had infections and 1/34 (2.9%) developed pancytopenia. In univariate and multivariate Cox regression analyses, FVIII inhibitor titer & GE;20 BU/mL was the only significant prognostic factor affecting time to CR. No variable had significant effect on OS. ConclusionFVIII inhibitory antibody titer & GE;20 BU/mL appears to be an important predictor of time to complete response in patients with acquired hemophilia A treated with immunosuppressive therapy.